News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cenix BioScience GmbH Follows up Successful RNAi-Based Target Discovery Screens with Target Validation Study for AstraZeneca PLC (AZN)


3/19/2009 9:33:55 AM

DRESDEN, Germany--(BUSINESS WIRE)--Cenix BioScience GmbH, a leading RNA interference (RNAi)-focused contract research organization, today announced that it has initiated a second research project under its existing framework research agreement with AstraZeneca Pharmaceuticals LP, one of the world’s leading pharmaceutical companies.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES